Mereo BioPharma (MREO) Depreciation and Depletion (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Depreciation and Depletion of $44000.0 for Q1 2026, up 15.79% year-on-year from $38000.0 in Q1 2025, and down 44.3% on a QoQ basis from $79000.0 in Q4 2025.
Mereo BioPharma (MREO) Depreciation and Depletion (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Depreciation and Depletion for 4 consecutive years, with $44000.0 the latest figure, recorded in Q1 2026.
- Quarterly Depreciation and Depletion rose 15.79% year-over-year to $44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $323000.0 (up 17.03% YoY) and the FY2025 annual result came in at $200000.0, up 39.86% from the prior year.
- Depreciation and Depletion fell to $44000.0 in Q1 2026 per MREO's latest filing, from $79000.0 in the prior quarter.
- Over the last five years, Depreciation and Depletion for MREO reached as high as $100000.0 in Q2 2023 and fell as low as $38000.0 in Q4 2024.
- A 4-year average of $73307.7 and a median of $79000.0 in 2025 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2024 — Depreciation and Depletion tumbled 46.48% — and 2025, when it jumped 107.89%.
- Year by year, Depreciation and Depletion stood at $71000.0 in 2023, then tumbled by 46.48% to $38000.0 in 2024, then soared by 107.89% to $79000.0 in 2025, then sank by 44.3% to $44000.0 in 2026.
- According to Business Quant data, Depreciation and Depletion over the past three periods registered $44000.0, $79000.0, and $100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 39.39 Mn |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | - |
| 10 | Mereo BioPharma | 228.59 Mn | 228.59 Mn | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 79,000.00 |
| Dec 31, 2025 | 79,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 41,000.00 |
| Mar 31, 2024 | 41,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Dec 31, 2023 | 71,000.00 |